ReviewEMBO molecular medicine2011
Chemokines: established and novel targets in atherosclerosis.
Review in EMBO molecular medicine, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 56 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
56 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Positive association between lymphotoxin-alpha variation rs909253 and cancer risk: a meta-analysis based on 36 case-control studies.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2014Pooled it
- Chemokine CCL2 Mediates Neuroglial Crosstalk and Drives Chronic Pain Pathogenesis.Neuroscience bulletin · 2025Review
- The role of CXCL16 in atherosclerosis: from mechanisms to therapy.Frontiers in immunology · 2025Review
- Human Plaque Myofibroblasts to Study Mechanisms of Atherosclerosis.Journal of the American Heart Association · 2023Article
- The Crossroads of the Coagulation System and the Immune System: Interactions and Connections.International journal of molecular sciences · 2023Review
- Article
- Accuracy of PET quantification in [Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2022Article
- Platelets, Thromboinflammation and Neurovascular Disease.Frontiers in immunology · 2022Review
- A bibliometric analysis of T cell and atherosclerosis.Frontiers in immunology · 2022Article
- Identification of potential biomarkers and pathways associated with carotid atherosclerotic plaques in type 2 diabetes mellitus: A transcriptomics study.Frontiers in endocrinology · 2022Article
- Article
- [Association betweenBeijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences · 2020Article
- Designed CXCR4 mimic acts as a soluble chemokine receptor that blocks atherogenic inflammation by agonist-specific targeting.Nature communications · 2020Article
- Structural characterization of anti-CCL5 activity of the tick salivary protein evasin-4.The Journal of biological chemistry · 2020Article
- Phenolic extracts from whole wheat biofortified bread dampen overwhelming inflammatory response in human endothelial cells and monocytes: major role of VCAM-1 and CXCL-10.European journal of nutrition · 2020Article
- Tick Saliva Protein Evasin-3 Allows for Visualization of Inflammation in Arteries through Interactions with CXC-Type Chemokines Deposited on Activated Endothelium.Bioconjugate chemistry · 2020Article
- Cross-kingdom mimicry of the receptor signaling and leukocyte recruitment activity of a human cytokine by its plant orthologs.The Journal of biological chemistry · 2020Article
- Carotenoids Inhibit Fructose-Induced Inflammatory Response in Human Endothelial Cells and Monocytes.Mediators of inflammation · 2020Article
- Role of Neutrophil-Derived S100B in Acute Myocardial Infarction Patients From the Han Chinese Population.Frontiers in cardiovascular medicine · 2020Article
- Systematic analysis of long non-coding RNA and mRNA expression changes in ApoE-deficient mice during atherosclerosis.Molecular and cellular biochemistry · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In their role as small chemotactic cytokines, chemokines are crucial mediators and regulators of leukocyte trafficking during immune surveillance and inflammation. Their involvement in the development and progression of inflammatory diseases has been subject of intense investigation. Concordantly, the chemokine system has been explored in search for therapeutic targets to prevent or treat inflammatory disorders, such as atherosclerosis. Targeting the chemokine system offers various entry points for a causative treatment of this widespread and chronic illness. Although this approach has encountered some setbacks, several innovative compounds are currently in an advanced stage of development. In this review, the current standing of this dynamic field is highlighted and the potential advantages and drawbacks of particular strategies are discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.